Verde Science (VRCI-OTCQB) is a biotech company in the startup phase that focuses on research and development in the pharmaceutical industry. The company has established a highly skilled R&D team with expertise in various scientific fields to isolate new drugs and develop innovative delivery systems for medical treatments. Verde Science's primary focus is on using Cannabis-based extracts to develop effective formulations for treating conditions such as migraines, pain management, appetite loss due to chemotherapy, multiple sclerosis, and seizures. The company's research will primarily take place in India to leverage lower costs and expedited response to new developments, setting them apart in the biotech space.

Verde Science has achieved significant milestones in its history, such as establishing a strong R&D team with expertise in Bioprocess Technology, Nanotechnology, Pharmacology, and Medical Device Design. The company has identified promising molecules in the Marijuana plant for the development of important pharmaceutical formulations. Additionally, Verde Science has made headlines by appointing a renowned doctor to lead a study on Huntingdon's Disease, sponsoring/ presenting at the Huntington Study Group Annual Conference, and announcing plans to study Cannabis preparations for treating the disease. These milestones showcase Verde Science's commitment to cutting-edge research and development in the pharmaceutical sector.

Verde Science has been involved in several notable case studies related to the isolation of new drugs and development of novel drug delivery systems for medical treatments. The company's research focuses on identifying molecules in the Marijuana plant with promising therapeutic potential for conditions like migraines, pain management, and seizures. Verde Science's dedication to cutting-edge research and innovative solutions demonstrates their commitment to advancing pharmaceutical science and improving patient outcomes. These case studies underscore Verde Science's expertise in bioprocess technology, nanotechnology, and pharmacology, positioning them as a leader in the development of novel pharmaceutical formulations.

Verde Science has experienced key events in its history that have shaped its trajectory in the pharmaceutical industry. These events include appointing a renowned doctor to lead a study on Huntingdon's Disease, sponsoring/ presenting at the Huntington Study Group Annual Conference, and announcing plans to study Cannabis preparations for treating the disease. These milestones demonstrate Verde Science's dedication to advancing medical research and developing innovative treatments for complex disorders. Additionally, the company's focus on cost-effective research in India highlights their strategic approach to drug development and sets them apart in the biotech industry.